Drug Development

Articles

Novartis has launched the prefilled syringe formulation of Lucentis (ranibizumab) in Germany, with other markets to follow throughout 2014. The prefilled syringe formulation has been specifically designed for intraocular injection to enhance patient safety and convenience for the treating clinician.

Novartis Launches Lucentis Prefilled Syringe in Europe

The Pediatric Praziquantel Consortium has been awarded a research grant from the Japanese Global Health Innovative Technology (GHIT) Fund. The grant will be used to fund the Consortium's clinical development program of a newly developed praziquantel pediatric formulation targeted for use in very young children, including infants and toddlers, infected with schistosomiasis.

Pediatric Praziquantel Consortium Receives US$1.86 Million Grant for the Development of Pediatric Formulations

Steve Bates, chief executive officer of the BioIndustry Association.

To gain insights into the current trends of the biotechnology sector in the United Kingdom, Pharmaceutical Technology Europe spoke with Steve Bates, chief executive officer of the BioIndustry Association (BIA), the trade association for biotech companies in the UK.

UK Biotech Gains Momentum

HHS plan makes progress in ensuring availability of safe vaccines.

FDA Details National Vaccine Plan

Schott's 20-mL TopPac prefillable polymer syringe simplifies the infusion-therapy preparation process.

SCHOTT Introduces Prefillable Polymer Syringe for Infusion Therapy Devices

Adeline Siew is editor for Pharmaceutical Technology Europe. She is also science editor for Pharmaceutical Technology.

Despite the progress made in nanomedicine development, there are several issues that remain unresolved. Raj Bawa, PhD, provides insight.

Current issues with nanomedicines

Jill Wechsler is Pharmaceutical Technology's Washington Editor, jillwechsler7@gmail.com.

Accelerated testing and production create challenges in documenting product quality.

Manufacturers Struggle with Breakthrough Drug Development

Nanomedicines can offer promising benefits in the diagnosis and treatment of diseases but there are still concerns about the safety and quality of these therapeutics partly because of the lack of clear regulatory guidance. Scott McNeil, PhD, director of the Nanotechnology Characterization Laboratory (NCL), spoke with Pharmaceutical Technology about nanomedicine characterization.

Characterization of nanomedicines

Surendra Nimesh, PhD, is an assistant professor in the Department
of Biotechnology at the School of Life Sciences, Central University of Rajasthan, Ajmer, RAjasthan, India.

Nidhi Gupta, PhD, is a research scientist in the Department of Biotechnology, the IIS University, Jaipur, Rajasthan, India.

Advances in nanomedicine have provided several potential candidates for safe and effective delivery of siRNA.

Perspectives and Challenges of Nanomedicine in Gene Silencing

With nanomedicines on the rise, a new class of non-biological complex drugs (NBCDs), which include nanosimilars, has emerged. As drug regulators are faced with the challenge of defining a framework to ensure the safe introduction of the follow-on nano-therapeutics, Stefan Muhlebach explains why NBCDs cannot be assessed using the standard generic or biosimilar approaches.

Formulation and Drug Delivery